GlassScriptPhysician profile
Michele A Candelore
NPI 1720146566
$12,645.81
in general payments reported to CMS, 2019-2025
57 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $1,968 · 2021: $2,931 · 2022: $1,832 · 2023: $1,967 · 2024: $1,536 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,690 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,689.71 |
| Education | $174.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,246.38 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,234.27 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,042.71 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $999.82 | 2019-2025 | |
| Astellas Pharma US INC | $920.82 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $713.34 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $585.41 | 2019-2025 | |
| Amarin Pharma, INC. | $547.31 | 2019-2022 | |
| Lilly USA, LLC | $493.51 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $490.05 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Merck Sharp & Dohme LLC | $475.83 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $338.94 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Allergan, INC. | $336.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.66 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $246.57 | 2019-2023 | Uzedy |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Candelore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.